Press release April 7, 2009
Diamyd Majority owners exercise 10,000 warrants each
Diamyd Medical is announcing today that the company's two principal owners,
Bertil Lindquist and Anders Essen-Möller, is each converting 10,000 Diamyd TO 2B
warrants into shares in Diamyd Medical AB. The exercise price is SEK 100 per
share.
The transaction is being carried out by exercise of the warrants that both
principal owners previously acquired from Diamyd Medical's President and CEO,
Elisabeth Lindner.
The warrants Diamyd TO 2B are traded until April 8 on First North Stock
Exchange, and can be converted into series B shares in Diamyd Medical AB from
March 16 until April 17, 2009. The exercise price is SEK 100.
For additional information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Tel: +46 8 6610026
For pictures and press material, please contact:
Alexandra Fleetwood, Director Communications Diamyd Medical AB (publ.),
alexandra.fleetwood@diamyd.com
Tel: +46 8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish biopharmaceutical company focusing on the
development of pharmaceuticals for the treatment of autoimmune diabetes and its
complications. The company's most advanced project is the GAD-based drug Diamyd®
for type 1 diabetes. Phase III trials for this drug are in progress in both the
US and Europe. In addition, the Company has initiated clinical studies in the US
in the area of chronic pain, using its Nerve Targeting Drug Delivery System. The
Company has also out-licensed the use of GAD for the treatment of Parkinson's
disease.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on the OMX
Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's website; www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
(www.omxnordicexchange.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
